These studies include an assessment of cabozantinib alone and in combination with fulvestrant in patients with metastatic HR+ disease and known bone metastases (ClinicalTrials.gov NCT01441947), a study of cabozantinib monotherapy in patients with triple-negative MBC (ClinicalTrials.gov NCT01738438), and a study of cabozantinib (with trastuzumab for HER2+ disease) in BC patients with brain metastasis (ClinicalTrials.gov NCT02260531). The gene discussed is ERBB2; the disease is breast cancer.